Zantac Cancer Defendants Have Filed Motions To Dismiss The Cases
A federal judge is considering several motions filed by defense attorneys to dismiss as part of the multidistrict litigation process
Thursday, May 27, 2021 - Hundreds of lawsuits against Sanofi, the maker of Zantac have been organized into multidistrict litigation (MDL) to streamline administrative proceedings, and to interview scientific expert witnesses. Expert testimony varies regarding their studies that concluded ranitidine causes cancer. The first bellwether Zantac cancer trials may happen as early as 2023 after MDL procedures are completed. At present, defense attorneys for the companies in question have filed several motions to dismiss the cases based on "the failure to state a claim, to dismiss brand-name manufacturer innovator liability claims, to dismiss retailer and pharmacy defendants, to dismiss drug distributors, to dismiss medical monitoring class action complaints and other claims," according to the filing reported by AboutLawsuits.com. Some legal pundits in the media think that more than 70,000 lawsuits await a group of companies including Swiss-based Sanofi, the maker of Zantac (ranitidine) heartburn and acid reflux medicine, given that Zantac had around 15 million US users at the time of the 2020 recall. Sanofi, GalaxoSmithKline, and others are being held accountable for fraud and negligence for not adequately testing the drug before and during offering it to the public for sale. Plaintiffs are asking for lump-sum monetary compensation and punitive damages for failing to warn that taking Zantac could cause cancer. Taking Zantac regularly for more than one year may lead to developing a wide range of cancer of the digestive system. Plaintiffs have developed cancer of the throat, esophagus, stomach, intestinal, bladder, kidney, prostate, colon, and other cancer, and blame it on taking ranitidine, the active ingredient in Zantac. Visit Zantac antacid cancer lawsuit to learn more.
Zantac was recalled by the US Food and Drug Administration when studies confirmed accusations against the heartburn drug. A citizen‘s petition by fledgling online prescription drug testing pharmacy Valisure called out ranitidine for degrading into a deadly carcinogen. Valisure CEO David Light wrote to the FDA, "The undersigned, on behalf of Valisure LLC and ValisureRX LLC ...submits this Citizen Petition according to Sections 301(etc) of the Federal Food, Drug, and Cosmetic Act... to request the Commissioner of Food and Drugs to issue a regulation, revise industry guidance, and request a recall and suspend sales of ranitidine from the US market and take such other actions set forth below." The petition continued to describe the magnitude of the ranitidine Zantac cancer scare, "...detected extremely high levels of N-Nitrososdimethylamine (‘NDMA‘), a probable human carcinogen, in every lot tested, across multiple manufacturers and dosage forms of the drug ranitidine. The Food and Drug Administration (‘FDA‘) has established a permissible daily intake limit for the probable human carcinogen, NDMA, of 96 ng. Valisure has detected NDMA above 3,000,000 ng per tablet when analyzing ranitidine products, likely due to an inherent instability of the ranitidine molecule." Further studies by Valisure and Sloan Memorial Cancer Hospital in New York, and other studies, have confirmed that ranitidine breaks down naturally when introduced to conditions of high temperatures and nitrates in the body to form N-nitrosomethylamine (NDMA), a deadly carcinogen used by cancer researchers to induce tumors in laboratory test animals.
